RenovoRx, Inc. (RNXT)
Automate Your Wheel Strategy on RNXT
With Tiblio's Option Bot, you can configure your own wheel strategy including RNXT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNXT
- Rev/Share 0.0076
- Book/Share 0.4191
- PB 3.293
- Debt/Equity 0.0141
- CurrentRatio 9.0697
- ROIC -1.0108
- MktCap 50469636.0
- FreeCF/Share -0.3286
- PFCF -4.8924
- PE -4.2652
- Debt/Assets 0.0116
- DivYield 0
- ROE -1.1958
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald Kocak - VP Controller and Principal Accounting Officer Conference Call Participants Rafay Khalid - Ascendiant Capital Markets Operator Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 Financial and Operational Highlights Conference Call. All participants will be in a listen-only mode.
Read More
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.
Read More
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
Published: May 01, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Ev.
Read More
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial. Johns Hopkins Medicine becomes the newest addition to a disting.
Read More
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
Published: April 04, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will present at the LD Micro Invitational XV: New York 2025 conference taking place at the Westin Grand Central Hotel, New York, NY on April 10, 2025. Mr. Bagai will discuss recent corporate m.
Read More
About RenovoRx, Inc. (RNXT)
- IPO Date 2021-08-26
- Website https://renovorx.com
- Industry Biotechnology
- CEO Mr. Shaun R. Bagai
- Employees 10